Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic interaction between cabazitaxel and darolutamide in mCRPC
2020-000823-38Phase 2Completed
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Apr 2020
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabazitaxel and darolutamide in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Erasmus MC Cancer Institute. Primary endpoint: AUC of cabazitaxel. Started Apr 2020; status: completed.
02
Drugs
cabazitaxeldarolutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2020-000823-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000823-38.